Resona Asset Management Co. Ltd. Takes $695,000 Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Resona Asset Management Co. Ltd. purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 8,902 shares of the company’s stock, valued at approximately $695,000.

Several other institutional investors and hedge funds have also bought and sold shares of PBH. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock valued at $126,274,000 after purchasing an additional 49,331 shares during the period. Geode Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after acquiring an additional 21,951 shares during the last quarter. Congress Asset Management Co. grew its holdings in Prestige Consumer Healthcare by 5.0% in the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after acquiring an additional 43,619 shares during the last quarter. Boston Trust Walden Corp increased its position in shares of Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after acquiring an additional 252,089 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after acquiring an additional 33,844 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock opened at $80.66 on Friday. The business’s fifty day moving average is $84.43 and its 200 day moving average is $79.75. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This represents a 8.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday. Royal Bank of Canada upped their target price on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a report on Friday, March 21st. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.